Filing Flows › Comparisons › RANI vs ALMS
Rani Therapeutics Holdings vs Alumis: RANI and ALMS compared
Rani Therapeutics Holdings is the larger company: $1.7M of revenue in its latest quarter (Q2 2026) against $1.7M for Alumis (Q2 2026).
Where the money goes: RANI and ALMS
Rani Therapeutics Holdings (RANI) · Q2 2026
Rani Therapeutics Holdings, Q2 2026: revenue $1.7M, operating margin -516.9%, net loss $8.4M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
Alumis (ALMS) · Q2 2026
Alumis, Q2 2026: revenue $1.7M (-38% year over year), net loss $142M, operating cash flow −$81.5M. The chart follows the revenue to costs, profit and cash.
| Rani Therapeutics Holdings (RANI) | Alumis (ALMS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.7M | $1.7M |
| Revenue growth, Y/Y | — | -38% |
| Operating margin | -516.9% | n/m |
| Net earnings | −$8.4M | −$142M |
| Net margin | -493.0% | — |
| Operating cash flow | −$9.0M | −$81.5M |
Questions
Which is bigger, Rani Therapeutics Holdings or Alumis?
Rani Therapeutics Holdings is the larger company: $1.7M of revenue in its latest quarter (Q2 2026) against $1.7M for Alumis (Q2 2026).
More: Rani Therapeutics Holdings earnings · how Rani Therapeutics Holdings makes money · Alumis earnings · how Alumis makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.